NC318, an Anti-Siglec-15 Humanized Monoclonal Antibody, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated Non Small Cell Lung Cancer (LUNG-SPORE 2023) - May 25, 2023 - Pres time: Jun 12, 2023; 12:05 PM - 12:17 PM; P2 | N=25 | NCT04699123 | "NC318 alone and in combination with pembrolizumab is well tolerated and has activity in pts previously treated with PD1 axis inhibitor therapy."
P2 data
|
|
Gettinger, Scott; Goldberg, Sarah B; Chiang, Anne C; Wilson, Frederick H; Rowen, Elin; Gerrish, Heather; Duffield, Emily; Davies, Marianne; Dest, Vanna; Jackson, Roliya; Pope, Jennifer; Mynt, Han; Langermann, Solomon; Cheng, Wei; Herbst; Roy S
|